THIRD QUARTER IN BRIEF
- Collaboration agreement for clinical study with tasquinimod in myelofibrosis signed (July 31)
- Tasquinimod successfully completed dose optimization in patients with multiple myeloma and advances into the pre-planned expansion cohort (September 11)
- Clinical safety and preclinical ocular biodistribution for laquinimod eye drops presented at the IOIS meeting is made available on Active Biotech's website (September 13)
EVENTS AFTER THE END OF THE PERIOD
- Preclinical data of tasquinimod in myelofibrosis awarded oral presentation at ASH 2023 (November 2)
- The board of directors resolved on November 9, based on the authorization from the general meeting, to carry out a rights issue of approximately SEK 51 million (before issue costs) to secure financing of the ongoing and planned development programs for tasquinimod and laquinimod
FINANCIAL SUMMARY
| SEK M | Jul-Sep | Jan-Sep | Full year | ||
| 2023 2022 | 2023 2022 | 2022 | |||
| Net sales | - | - | - | - | - |
| Operating profit/loss | -10.6 | -13.4 | -33.7 | -42.6 | -57.9 |
| Profit/loss after tax | -10.6 | -13.4 | -33.3 | -43.4 | -58.4 |
| Earnings per share (SEK) | -0.04 | -0.06 | -0.13 | -0.19 | -0.25 |
| Cash and cash equivalents (at close of period) | 5.6 | 55.0 | 41.8 | ||
The report is also available at www.activebiotech.com
For further information, please contact:
Helén Tuvesson, CEO, +46 46 19 21 56, helen.tuvesson@activebiotech.com
Hans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com
About Active Biotech
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: The wholly owned small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is in clinical development for treatment of non-infectious uveitis and a clinical phase I study with a topical ophthalmic formulation has been concluded. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.
This information is information that Active Biotech is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-11-09 08:30 CET.
